Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.

Author(s): Punzi H, Shojaee A, Waverczak WF, Maa JF

Affiliation(s): Trinity Hypertension Research Institute, Punzi Medical Center, Carrollton, TX, USA.

Publication date & source: 2011-06, J Clin Hypertens (Greenwich)., 13(6):422-30. Epub 2011 Feb 1.

Publication type: Comparative Study; Research Support, Non-U.S. Gov't

A subgroup analysis of a prospective, open-label, single-arm titration study in patients with hypertension and type 2 diabetes or obesity is reported. The primary end point was the change from baseline in mean 24-hour ambulatory systolic blood pressure (BP) after 12 weeks. Patients received amlodipine 5 mg/d and were uptitrated (if seated [Se] BP was >/= 120/80 mm Hg) at 3-week intervals to amlodipine/olmesartan medoxomil 5/20 mg/d, 5/40 mg/d, and 10/40 mg/d. In patients with diabetes and obesity, baseline 24-hour ambulatory BP (+/- standard deviation) was 145.6 +/- 10.4/83.1 +/- 9.0 mm Hg and 143.7 +/- 9.8/84.9 +/- 8.2 mm Hg, respectively, and baseline SeBP was 159.1 +/- 11.3/90.3 +/- 9.2 mm Hg and 158.2 +/- 12.5/94.2 +/- 8.5mm Hg, respectively. Changes from baseline in mean 24-hour ambulatory BP (+/- standard error of the mean) were -21.5 +/- 1.8/-12.6 +/- 1.1 mm Hg and 21.6 +/- 1.1/13.4 +/- 0.8 mm Hg in patients with diabetes and obesity, respectively. Prespecified 24-hour ambulatory BP targets of < 130/80 mm Hg, < 125/75 mm Hg, and < 120/80 mm Hg were achieved by 79.1%, 53.5%, and 39.5% of patients with diabetes and 75.3%, 58.4%, and 43.8% of obese patients, respectively. The SeBP goal of < 130/80 mm Hg was achieved by 26.1% of patients with diabetes and <140/90 mm Hg was achieved by 78.1% of obese patients. (c) 2011 Wiley Periodicals, Inc.